Business
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
HAYWARD, Calif., January 06, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond...
About this update from Pulse Biosciences, Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e3546ff55f4c88cdd5ee24c1e9edddba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BXFEILikzTqDJUcrCnmftQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e3546ff55f4c88cdd5ee24c1e9edddba","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/udR9WHrFU64kvKosJK4Lgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/e3546ff55f4c88cdd5ee24c1e9edddba","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HAYWARD, Calif., January 06, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation at the 31st Annual AF Symposium 2026 meeting in February.","length":457,"tagName":"p"},{"type":"text","content":"This late breaking data will be presented by Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY, and include 6-month and 12-month follow-up data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study conducted in Europe. The Company plans to provide specifics on presentation times in late January.","length":376,"tagName":"p"},{"type":"text","content":"About Pulse Biosciences®","length":24,"tagName":"p"},{"type":"text","content":"Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as s...